Literature DB >> 8312369

The biochemistry and clinical features of galactosialidosis.

Y Okamura-Oho1, S Zhang, J W Callahan.   

Abstract

Galactosialidosis is a heterogeneous disorder that is manifested in infantile, late infantile, juvenile/adult, and atypical forms. In every instance the primary defect is in the ability of protective protein to associate with beta-galactosidase and neuraminidase to protect them from intralysosomal proteolysis. The protective protein is in reality a serine protease that displays both cathepsin A and C-terminal deamidase activity. We summarize the major clinical features of each form, and the range of storage products accumulated. The concept of an intralysosomal complex containing beta-galactosidase and neuraminidase in addition to protective protein seems irrefutable but major gaps exist in our understanding of how the complex is formed and in what subcellular organelles, how it is sustained, and the protein domains contributed by the constituent enzymes that play a pivotal role in this process.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8312369     DOI: 10.1016/0925-4439(94)90002-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Molecular mechanism of lysosomal sialidase deficiency in galactosialidosis involves its rapid degradation.

Authors:  M V Vinogradova; L Michaud; A V Mezentsev; K E Lukong; M El-Alfy; C R Morales; M Potier; A V Pshezhetsky
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

2.  Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus.

Authors:  N M Carroll; E A Chiocca; K Takahashi; K K Tanabe
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

3.  Ultrastructural change of ligamentum flavum in galactosialidosis.

Authors:  Sueo Nakama; Suguru Hagiwara; Masaki Kato; Yuji Kanaya; Hideaki Watanabe
Journal:  Eur Spine J       Date:  2013-08-30       Impact factor: 3.134

4.  Early proteolytic cleavage with loss of a C-terminal fragment underlies altered processing of the beta-galactosidase precursor in galactosialidosis.

Authors:  Y Okamura-Oho; S Zhang; W Hilson; A Hinek; J W Callahan
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

5.  Effects of gene therapy on cardiovascular symptoms of lysosomal storage diseases.

Authors:  Edina Poletto; Gabriela Pasqualim; Roberto Giugliani; Ursula Matte; Guilherme Baldo
Journal:  Genet Mol Biol       Date:  2019-05-23       Impact factor: 1.771

6.  Structural basis for substrate specificity of mammalian neuraminidases.

Authors:  Victoria Smutova; Amgad Albohy; Xuefang Pan; Elena Korchagina; Taeko Miyagi; Nicolai Bovin; Christopher W Cairo; Alexey V Pshezhetsky
Journal:  PLoS One       Date:  2014-09-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.